Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: Possible implications in abnormal mucin O-glycosylation

Oncotarget

Volumn 5, Issue 2, 2014, Pages 544-560

  Wang, Zhi Qiang ^a,b   Bachvarova, Magdalena ^b   Morin, Chantale ^b   Plante, Marie ^a,b   Gregoire, Jean ^a,b   Renaud, Marie Claude ^a,b   Sebastianelli, Alexandra ^a,b   Bachvarov, Dimcho ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Epithelial ovarian cancer; DNA hypomethylation; GALNT3; Microarrays; Mucin O glycosylation; Progression free survival

Indexed keywords

BETA CATENIN; CELL ADHESION MOLECULE; MUCIN 1; UVOMORULIN; MUCIN; N ACETYLGALACTOSAMINYLTRANSFERASE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; N ACETYLGALACTOSAMINYLTRANSFERASE 3 GENE; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; S PHASE CELL CYCLE CHECKPOINT; SURVIVAL TIME; TUMOR GENE; TUMOR SUPPRESSOR GENE; CELL GROWTH; CELL MOTION; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GLYCOSYLATION; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; TISSUE MICROARRAY; TUMOR CELL LINE;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLYCOSYLATION; HUMANS; MUCINS; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84896720044     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1652     Document Type: Article

References (73)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.
2. Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S and Pignata S. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert review of anticancer therapy. 2010; 10(1):47-60.
3. Jones PA and Baylin SB. The epigenomics of cancer. Cell. 2007; 128(4):683-692.
4. Balch C, Fang F, Matei DE, Huang TH and Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology. 2009; 150(9):4003-4011.
5. Momparler RL. Cancer epigenetics. Oncogene. 2003; 22(42):6479-6483.
6. Maier S, Dahlstroem C, Haefliger C, Plum A and Piepenbrock C. Identifying DNA methylation biomarkers of cancer drug response. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2005; 5(4):223-232.
7. Szyf M, Pakneshan P and Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer letters. 2004; 211(2):133-143.
8. Bauerschlag DO, Ammerpohl O, Brautigam K, Schem C, Lin Q, Weigel MT, Hilpert F, Arnold N, Maass N, Meinhold-Heerlein I and Wagner W. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology. 2011; 80(1-2):12-20.
9. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE and Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC medical genomics. 2008; 1:47.
10. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S and Nephew KP. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC medical genomics. 2009; 2:34.
11. Keita M, Wang ZQ, Pelletier JF, Bachvarova M, Plante M, Gregoire J, Renaud MC, Mes-Masson AM, Paquet ER and Bachvarov D. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecologic oncology. 2013; 128(2):356-363.
12. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA and Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012; 22(6):736-756.
13. Hang HC and Bertozzi CR. The chemistry and biology of mucin-type O-linked glycosylation. Bioorganic & medicinal chemistry. 2005; 13(17):5021-5034.
14. Madsen CB, Petersen C, Lavrsen K, Harndahl M, Buus S, Clausen H, Pedersen AE and Wandall HH. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PloS one. 2012; 7(11):e50139.
15. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC and Li Y. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecologic oncology. 2007; 105(3):695-702.
16. Yuan Z, Wong S, Borrelli A and Chung MA. Downregulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochemical and biophysical research communications. 2007; 362(3):740-746.
17. Nomoto M, Izumi H, Ise T, Kato K, Takano H, Nagatani G, Shibao K, Ohta R, Imamura T, Kuwano M, Matsuo K, Yamada Y, Itoh H and Kohno K. Structural basis for the regulation of UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. Cancer research. 1999; 59(24):6214-6222.
18. Ozaki T and Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. Journal of biomedicine & biotechnology. 2011; 2011:603925.
19. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ and Peters JM. Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. The Journal of biological chemistry. 2004; 279(22):23719-23727.
20. Su B, Bu Y, Engelberg D and Gelman IH. SSeCKS/Gravin/ AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C-Raf/MEK/ERK pathway. The Journal of biological chemistry. 2010; 285(7):4578-4586.
21. Zhang LL, Shao SL and Wu Y. [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chinese journal of cancer. 2010; 29(1):25-29.
22. Lee KB, Byun HJ, Park SH, Park CY, Lee SH and Rho SB. CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer letters. 2012; 315(1):86-95.
23. Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M and Levitzki A. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer research. 2013; 73(14):4383-4394.
24. Chakrabarty S and Kondratick L. Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer biology & therapy. 2006; 5(2):189-197.
25. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L and Kuliopulos A. Identification of a metalloproteasechemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer research. 2010; 70(14):5880-5890.
26. Al-Alem LF, McCord LA, Southard RC, Kilgore MW and Curry TE, Jr. Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10. Biology of reproduction. 2013; 89(3):73.
27. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR and Buckanovich RJ. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. The Journal of clinical investigation. 2011; 121(8):3206-3219.
28. Theriault BL and Nachtigal MW. Human ovarian cancer cell morphology, motility, and proliferation are differentially influenced by autocrine TGFbeta superfamily signalling. Cancer letters. 2011; 313(1):108-121.
29. Theriault BL, Shepherd TG, Mujoomdar ML and Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis. 2007; 28(6):1153-1162.
30. Do TV, Kubba LA, Du H, Sturgis CD and Woodruff TK. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Molecular cancer research : MCR. 2008; 6(5):695-705.
31. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, Chan DC, Chan QK and Cheung AN. Tyrosine kinase B receptor and BDNF expression in ovarian cancers-Effect on cell migration, angiogenesis and clinical outcome. Cancer letters. 2009; 281(2):151-161.
32. Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, Gasson JC, Karlan BY and Slamon DJ. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecologic oncology. 2010; 119(2):337-344.
33. Furuya M. Analysis of matrix metalloproteinases and related tissue inhibitors in cystic fluids of ovarian tumors. [Hokkaido igaku zasshi] The Hokkaido journal of medical science. 1999; 74(2):145-155.
34. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC and Annunziata CM. Activation of NF-?B Signaling by Inhibitor of NF-?B Kinase β Increases Aggressiveness of Ovarian Cancer. Cancer research. 2010; 70(10):4005-4014.
35. Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Matsumoto T and Sasaguri Y. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. British journal of cancer. 2013; 109(2):472-481.
36. Mochizuki Y, Ito KI, Izumi H, Kohno K and Amano J. Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas. Thyroid : official journal of the American Thyroid Association. 2013.
37. Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, Saibara T and Hollingsworth MA. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene. 2011; 30(49):4843-4854.
38. Inoue T, Eguchi T, Oda Y, Nishiyama K, Fujii K, Izumi H, Kohno K, Yamaguchi K, Tanaka M and Tsuneyoshi M. Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections-special reference to its association with lymph node metastases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2007; 20(2):267-276.
39. Onitsuka K, Shibao K, Nakayama Y, Minagawa N, Hirata K, Izumi H, Matsuo K, Nagata N, Kitazato K, Kohno K and Itoh H. Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma. Cancer science. 2003; 94(1):32-36.
40. Dosaka-Akita H, Kinoshita I, Yamazaki K, Izumi H, Itoh T, Katoh H, Nishimura M, Matsuo K, Yamada Y and Kohno K. N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. British journal of cancer. 2002; 87(7):751-755.
41. Shibao K, Izumi H, Nakayama Y, Ohta R, Nagata N, Nomoto M, Matsuo K, Yamada Y, Kitazato K, Itoh H and Kohno K. Expression of UDP-N-acetyl-alpha-Dgalactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer. 2002; 94(7):1939-1946.
42. Kato K, Takeuchi H, Kanoh A, Miyahara N, Nemoto-Sasaki Y, Morimoto-Tomita M, Matsubara A, Ohashi Y, Waki M, Usami K, Mandel U, Clausen H, Higashi N and Irimura T. Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis. Glycoconjugate journal. 2010; 27(2):267-276.
43. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G and Sprecher E. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nature genetics. 2004; 36(6):579-581.
44. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer research. 2010; 70(7):2759-2769.
45. Gomes J, Marcos NT, Berois N, Osinaga E, Magalhaes A, Pinto-de-Sousa J, Almeida R, Gartner F and Reis CA. Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2009; 57(1):79-86.
46. Matsumoto Y, Zhang Q, Akita K, Nakada H, Hamamura K, Tokuda N, Tsuchida A, Matsubara T, Hori T, Okajima T, Furukawa K and Urano T. pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen. Biochemical and biophysical research communications. 2012; 419(1):7-13.
47. Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, Barrois M, Dessen P, Kagedal B, Benard J, Osinaga E and Raguenez G. ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma. Clinical chemistry. 2006; 52(9):1701-1712.
48. Wang R, Yu C, Zhao D, Wu M and Yang Z. The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. Oncology reports. 2013; 30(2):667-676.
49. Ding MX, Wang HF, Wang JS, Zhan H, Zuo YG, Yang DL, Liu JY, Wang W, Ke CX and Yan RP. ppGalNAc T1 as a potential novel marker for human bladder cancer. Asian Pacific journal of cancer prevention : APJCP. 2012; 13(11):5653-5657.
50. Gao Y, Liu Z, Feng J, Sun Q, Zhang B, Zheng W and Ma W. Expression pattern of polypeptide N-acetylgalactosaminyltransferase-10 in gastric carcinoma. Oncology letters. 2013; 5(1):113-116.
51. Hua D, Shen L, Xu L, Jiang Z, Zhou Y, Yue A, Zou S, Cheng Z and Wu S. Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer. International journal of molecular medicine. 2012; 30(6):1267-1274.
52. Liu J, Yang L, Jin M, Xu L and Wu S. regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2. Molecular medicine reports. 2011; 4(6):1299-1305.
53. Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ, Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, Huang HC and Huang MC. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer research. 2011; 71(23):7270-7279.
54. Berois N, Gattolliat CH, Barrios E, Capandeguy L, Douc-Rasy S, Valteau-Couanet D, Benard J and Osinaga E. GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clinical chemistry. 2013; 59(1):225-233.
55. Guo JM, Chen HL, Wang GM, Zhang YK and Narimatsu H. Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-12 in gastric and colonic cancer cell lines and in human colorectal cancer. Oncology. 2004; 67(3-4):271-276.
56. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L and Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/ TRAIL. Nature medicine. 2007; 13(9):1070-1077.
57. Peng RQ, Wan HY, Li HF, Liu M, Li X and Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. The Journal of biological chemistry. 2012; 287(17):14301-14309.
58. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer cell. 2011; 20(1):104-118.
59. Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K and Sasaguri Y. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. British journal of cancer. 2011; 104(12):1882-1889.
60. Meany DL and Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clinical proteomics. 2011; 8(1):7.
61. Ten Hagen KG, Fritz TA and Tabak LA. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 2003; 13(1):1R-16R.
62. Carraway KL, 3rd, Funes M, Workman HC and Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Current topics in developmental biology. 2007; 78:1-22.
63. Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, Blixt O, Fourkala EO, Bueti D, Dawnay A, Ford J, Desai R, David L, Trinder P, Acres B, Schwientek T, et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British journal of cancer. 2013; 108(10):2045-2055.
64. Deng J, Wang L, Chen H, Li L, Ma Y, Ni J and Li Y. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer metastasis reviews. 2013.
65. Inoue M, Takahashi S, Yamashina I, Kaibori M, Okumura T, Kamiyama Y, Vichier-Guerre S, Cantacuzene D and Nakada H. High density O-glycosylation of the MUC2 tandem repeat unit by N-acetylgalactosaminyltransferase-3 in colonic adenocarcinoma extracts. Cancer research. 2001; 61(3):950-956.
66. Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, Bennett EP, Nielsen PA, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J and Clausen H. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1,-T2, and-T3. The Journal of biological chemistry. 1997; 272(38):23503-23514.
67. Bennett EP, Hassan H, Mandel U, Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG, Olofsson S and Clausen H. Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. The Journal of biological chemistry. 1999; 274(36):25362-25370.
68. Taylor PT and Haverstick D. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Journal of the National Cancer Institute. 2005; 97(2):151; author reply 152.
69. Keita M, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Trinh XB and Bachvarov D. The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell cycle. 2013; 12(6):972-986.
70. Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Tetu B, Bairati I and Bachvarov D. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Molecular oncology. 2011; 5(5):438-453.
71. Wang ZQ, Keita M, Bachvarova M, Gobeil S, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Trinh XB and Bachvarov D. Inhibition of RUNX2 Transcriptional Activity Blocks the Proliferation, Migration and Invasion of Epithelial Ovarian Carcinoma Cells. PloS one. 2013; 8(10):e74384.
72. Tollefsen SE and Kornfeld R. Isolation and characterization of lectins from Vicia villosa. Two distinct carbohydrate binding activities are present in seed extracts. The Journal of biological chemistry. 1983; 258(8):5165-5171.
73. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, Brenner DE and Lubman DM. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. Journal of proteome research. 2008; 7(4):1693-1703.